Dengue Vaccines Comprehensive Market Study with Focus on Key Drivers and Trends

Image Credit : businessmirror

Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has since spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths among children and adults in these regions.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/23

Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.

India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/23

Dengue Vaccines Market Outlook – Research Pipeline

There are approximately five vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.

You may be interested

Plastisols Market Applications, Types and Market Analysis to 2026
Chemicals and Polymer Science
Chemicals and Polymer Science

Plastisols Market Applications, Types and Market Analysis to 2026

Alex Mathew - August 14, 2018

Plastisols Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation,…

Business

Phytonutrients Market Revenue Growth Predicted by 2025

Mohit Joshi - August 14, 2018

Phytonutrients Market report provides the statistical analysis of “Phytonutrients Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The report helps…

Chemicals and Polymer Science

Citric Acid Market Headed for Growth and Global Expansion by 2026

Mohit Joshi - August 14, 2018

Citric Acid Market report provides the statistical analysis of “Citric Acid Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The…

Most from this category